International Stem Cell (ISCO) Share-based Compensation (2010 - 2026)

International Stem Cell (ISCO) has reported Share-based Compensation for 17 consecutive years, with $13.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation changed 0.27% year-over-year to $13.6 million in Q2 2026; TTM through Jun 2026 was $13.6 million, a 0.27% change from a year earlier, with the FY2025 full-year figure at $13.6 million, up 8.98% from the prior year.
• Share-based Compensation was $13.6 million for Q2 2026 at International Stem Cell, up from $64000.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $30.0 million in Q3 2023 and troughed at $64000.0 in Q4 2025.
• A 5-year average of $9.5 million and a median of $9.7 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 209.28% in 2023 and tumbled 58.25% in 2024, its largest moves.
• Over 5 years, Share-based Compensation stood at $109000.0 in 2022, then grew by 19.27% to $130000.0 in 2023, then declined by 23.08% to $100000.0 in 2024, then tumbled by 36.0% to $64000.0 in 2025, then jumped by 21168.05% to $13.6 million in 2026.
• The last three Share-based Compensation figures came in at $13.6 million (Q2 2026), $64000.0 (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.